載入中
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
一般交易時段
US$4.415
+US$0.055 · +1.26%
盤中時間採用ET。市場資料可能有所延遲。
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
日內區間
目前US$4.415
52週區間
目前US$4.415
盤中時間採用ET。市場資料可能有所延遲。
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
日內區間
目前US$4.415
52週區間
目前US$4.415
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8427.8萬 USD | 8914.9萬 USD | 3萬 USD | 131.6萬 USD | 550.6萬 USD |
| 銷貨成本 | 2042.3萬 USD | 2055.7萬 USD | — | 1712萬 USD | 21.3萬 USD |
| 毛利 | 6385.5萬 USD | 6859.2萬 USD | 3萬 USD | −1580.4萬 USD | 529.3萬 USD |
| 研究與開發 | 1318.1萬 USD | 1958萬 USD | 2026.6萬 USD | 1837.6萬 USD | 2027.3萬 USD |
| 銷售、一般及管理費用 | 2.3億 USD | — | 4728.4萬 USD | 1865.6萬 USD | 468.7萬 USD |
| 營業費用 | 2.43億 USD | 7167.5萬 USD | 6755萬 USD | 1971.2萬 USD | 2474.7萬 USD |
| 利息收入 | 1066.9萬 USD | — | — | — | 80萬 USD |
| 利息支出 | 259.9萬 USD | — | — | — | 10.6萬 USD |
| 折舊和攤銷 | 136.7萬 USD | 7.9萬 USD | 7.3萬 USD | 31.9萬 USD | 21.3萬 USD |
| 營業利益 | −1.79億 USD | −308.3萬 USD | −6752萬 USD | −3551.6萬 USD | −1945.4萬 USD |
| 淨利 | −1.71億 USD | 799.8萬 USD | −5436.5萬 USD | −3468.2萬 USD | −2024.3萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1049.86萬0.00%2.3兆 USD0.03%US$379.52-0.40%
State Street SPDR S&P Biotech ETFXBI975萬0.10%100.75億 USD0.35%US$147.01-2.14%
iShares Russell 2000 ETFIWM714.95萬0.01%785.63億 USD0.19%US$274.8-1.04%
Vanguard Extended Market ETFVXF457.69萬0.00%954億 USD0.05%US$231.42-0.89%
iShares Russell 2000 Growth ETFIWO254.45萬0.02%142.49億 USD0.24%US$350.63-1.34%
Vanguard Russell 2000 ETFVTWO212.59萬0.01%180億 USD0.06%US$110.99-1.09%
iShares Biotechnology ETFIBB206.46萬0.02%104.01億 USD0.44%US$197.82-2.71%
Schwab U.S. Small-Cap ETFSCHA142.73萬0.01%216.99億 USD0.03%US$32.305-0.94%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
